Close Menu

NEW YORK – The National Institute for Health and Care Excellence (NICE) in the UK on Thursday published a final draft guidance recommending that the National Health Service make available gilteritinib (Astellas' Xospata) monotherapy for patients with FLT3-mutated acute myeloid leukemia.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.